Awakening Oligodendrocyte Precursors: Recent Advances in Remyelination

The Scientist is bringing together a panel of experts to share their research into remyelination strategies, across diverse diseases, and to discuss the current body of evidence for oligodendrocyte precursor reprogramming.

May 27, 2016
The Scientist Marketing Team

 

Myelin provides important structural, electrical, and trophic support in the central nervous system (CNS), and several diseases interfere with normal myelination, causing axonal demyelination or hypomyelination. Defects in myelination impair normal action potential propagation and dampen axonal conductivity. Remediating the conductivity between neurons in the pathological setting has proven difficult, as oligodendrocyte precursor cell (OPC) reprogramming has not, to date, been feasible on a large scale. To explore whether or not remyelination is an achievable therapeutic target in diseases such as multiple sclerosis and schizophrenia, The Scientist is bringing together a panel of experts to discuss the current body of evidence. Attendees will have the opportunity to interact with the experts, ask questions, and seek advice on topics related to their research.

Topics to be covered:

  • Promotion of remyelination by resident OPCs
  • Addressing and overcoming demyelination and hypomyelination

View the Video Now

Meet the Speakers:

Steve Goldman, MD, PhD
URMC Distinguished Professor of Neurology and Neuroscience
Co-Director, Center for Translational Neuromedicine
University of Rochester Medical Center

 

Yasir Ahmed Syed, PhD
Postdoctoral Researcher
Department of Clinical Neurosciences
Cambridge Stem Cell Institute, University of Cambridge

 

R&D Systems
BioLegend